57results about How to "Inhibit overexpression" patented technology

The present invention relates to a method for isolating a polynucleotide of interest that is present in the genome of a first mycobacterium strain and/or is expressed by the first mycobacterium strain, where the polynucleotide of interest is also absent or altered in the genome of a second mycobacterium strain and/or is not expressed in the second mycobacterium. The method comprises: (a) contacting the genomic DNA of the first mycobacterium strain under hybridizing conditions with the DNA of a least one clone that belongs to a bacterial artificial chromosome (BAC) genomic DNA library of the second mycobacterium strain, and (b) isolating the polynucleotide of interest that does not form a hybrid with the DNA of the second mycobacterium strain. This invention further pertains to a Mycobacterium tuberculosis strain H37Rv genomic DNA library, as well as a Mycobacterium bovis BCG strain Pasteur genomic DNA library, and the recombinant BAC vectors that belong to those genomic DNA libraries. This invention also relates to a method, as well as a kit, for detecting a nucleic acid of a mycobacterium in a biological sample.

The invention belongs to the field of medical chemistry, relates to a novel pyridazinone BTK inhibitor as well as preparation and application thereof, in particular to a pyridazinone BTK inhibitor, apreparation method thereof, a pharmaceutical composition containing the same, and application thereof to treatment of Bruton's tyrosine kinase-related diseases.

The invention relates to the field of medicinal chemistry, relates to pyridazinone BTK inhibitors and an application thereof, and concretely relates to pyridazinone BTK inhibitors represented by formula (I), a preparation method thereof, a medicinal composition containing the compounds, and a use of the compounds or the medicinal composition in the treatment of Bruton's tyrosine kinase-related diseases.

The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant herpesvirus is used to confer immunity on fish, preferably on carps, more preferably on Cyprinus carpio, against a disease caused by koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3).

The invention relates to a method for manufacturing phenolic acid positions of vernonia anthelmintica and anti-inflammation application of the phenolic acid positions. The method includes smashing dried fruits of the vernonia anthelmintica; extracting extracts by the aid of organic solvents; separating and purifying the extracts by the aid of resin to obtain the phenolic acid positions of the vernonia anthelmintica. Main active ingredients of phenolic acid at the positions of the vernonia anthelmintica include 3, 4-dicaffeoyl-quinic acid, 3, 5-dicarffeoyl-quinic acid and 4, 5-dicaffeoyl-quinic acid, the total content of the phenolic acid ranges from 20% to 99%, excess release of nitric oxide of inflammation mediators can be obviously suppressed by the phenolic acid positions of the vernonia anthelmintica in inflammation response of mice macrophage RAW264.7 induced by lipopolysaccharide, excessive secretion of interleukin 6, interleukin 1 and tumor necrosis factors alpha of inflammation factors can be suppressed, excess expression of nitric oxide synthase and epoxidase 2 can be suppressed, and phosphorylation of nuclear factors kB can be suppressed. The method has the advantages that the phenolic acid positions of the vernonia anthelmintica has excellent anti-inflammation activity and can be used for preventing or treating inflammation due to the excess nitric oxide, the excess tumor necrosis factors alpha, the excess interleukin 6 or the excess interleukin 1.

The invention relates to the field of medicines, in particular relates to novel application of oleanolic acid and especially relates to application of preparation of a medicine for inhibiting skin inflammations. An experiment shows that the oleanolic acid can be used for effectively inhibiting the release of inflammatory factors, so that the inflammation diminishing aim is realized. The result shows that the oleanolic acid can be used for preparing a skin inflammation inhibitor.

The invention relates to the field of biological medicine, and discloses an application of marine-derived oligoguluronic acid. MdOA obtained by oxidation and degradation of sodium alginate can inhibit excessive NO production by an RAW264.7 cell induced by LPS, and the inhibition effect is concentration-dependent. According to the application, by adoption of an RT-PCR method, it is found that over-expressed mRNAs of iNOS and COX-2 in the RAW264.7 cell are reduced along with the increase of MdOA stimulation time and the relationship is concentration-dependent. By adoption of a Western Blot method, it is found that overexpression of iNOS protein and COX-2 protein can be inhibited by the MdOA. By adoption of an ELISA method, it is found that the MdOA can inhibit expression of intracellular related inflammatory cytokines comprising TNF-alpha, IL-6, IL-1beta, and the like. Therefore, the marine-derived oligoguluronic acid MdOA can be used for preparation of anti-inflammatory medicines.

The present invention discloses a novel protein called Synoviolin and a gene that encodes it. This protein is expressed specifically by synovial tissue and also accompanies the presence of an auto-antibody that recognizes this protein in rheumatoid arthritis (RA) patients. The protein according to the present invention and its antibody can be expected to be used as specific diagnostic markers for RA. In addition, the gene or protein according to the present invention may be used to permit the screening of drugs to treat RA. Moreover, the present invention provides synoviolin gene transgenic animals. The transgenic animals according to the present invention can be used as RA model animals in the development of pharmaceuticals to treat RA.

The present invention relates to a burn ointment for treating burns and scalds and the preparation method thereof, which pertains to the Chinese traditional patent medicines and the preparation technical field, the present invention aims at solving the technical problem of: providing the burn ointment which can promote the wound healing as soon as possible, prevent the wound infection, prevent and reduce the scar formation and the preparation method thereof. The parts by weight of the raw materials of the burn ointment are: champion bauhinia: 15 to 90; anoectochilus formosanus: 3 to 18; stearate: 1 to 10; glycerol stearate: 0.2 to 2; sesame oil: 2 to 20; liquid paraffin: 1 to 10; beeswax: 1 to 10; glycerol: 3 to 30; triethanolamine: 0.15 to 1.5; ethyl paraben: 0.01 to 0.2; distilled water: 5 to 50; borneol: 0.02 to 0.5. The preparation method is that the base materials are added in proportion after the pretreatments of powder making and solvent extraction according to the different characteristics of raw materials, so as to prepare the ointment. The external application of the present invention has the treatment effects of rapid pain stopping, fast wound healing, strong anti-infective ability and no scars, furthermore the use is convenient, the operation is simple and the cost is low.

The invention discloses a boron-containing compound, a pharmaceutical composition and a preparation method and application of the boron-containing compound. The boron-containing compound has a generalstructural formula (I), and nucleotide substances serve as small molecules required by DNA synthesis and are easily taken up by rapidly proliferating tumor cells in a large amount, so that 10B atomscombined with the nucleotide substances enter the nucleus of tumor cells together, and the boron-containing compound can kill tumors more effectively after neutron irradiation. Secondly, the boron agent synthesized by the compound belongs to an epidermal growth factor receptor (EGFR) inhibitor, produces synergistic tumor growth inhibition effect with BNCT, competitively blocks ATP (adenosine triphosphate) and receptor tyrosine kinase domain to inhibit EGFR overexpression effect, prevents DNA repair of tumor cells, and further inhibits growth, migration, differentiation and survival of the tumor cells.

The invention discloses application of baohuoside I in preparation of a drug for preventing and treating cerebral arterial thrombosis. The baohuoside I is adopted to prepare a drug for preventing and treating cerebral arterial thrombosis. The prepared pharmaceutical composition has a protective role on acute cerebral arterial thrombosis by verification of a series of animal experiments, and the measurement is associated with the baohuoside I for stopping reduction of PPARalpha and PPARgamma expression, and inhibiting of activation of an IkB/NF-kB channel, so as to inhibit overexpression of inflammatory factors such as 1L-1beta, TGFbeta1 and the like.

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

The invention provides a paclitaxel and fluoropyridazine BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition, characterized by comprising: an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is composed of paclitaxel and a BTK inhibitor represented by the formula (I); the mole ratio of the paclitaxel to the BTK inhibitor represented by the formula (I) in the active ingredient is (0.14-0.20):1. The pharmaceutical composition can be used for preparing a medicament for preventing and/or treating a disease associated with Bruton's tyrosine kinase, and the therapeutic effect is good.

The invention provides a taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition, which consists of an active ingredient and pharmaceutically acceptable adjuvants, whereinthe active ingredient is composed of taxol and a BTK inhibitor shown as formula (I) (as shown in Description); and the mole ratio of the taxol to the BTK inhibitor shown as formula (I) in the activeingredient is at (0.14-0.20) to 1. The pharmaceutical composition can be used for preparing medicines for preventing and/or treating diseases related to Bruton's tyrosine kinase, with a good therapeutic effect.

The invention belongs to the technical field of traditional Chinese medicines, and relates to an intestinal tract contrast agent for X-ray barium enema examination. The intestinal tract contrast agentfor X-ray barium enema examination consists of the following raw materials in parts by weight: 200-250 grams of barium sulfate, 70-90 grams of a traditional Chinese medicine composition and a properamount of water. A traditional Chinese medicine extract is prepared from the following raw material components: Radix Astragali, Semen Coicis, Radix Angelicae Dahuricae, Radix Sangusorbae, Radix Scutellariae, Radix Puerariae, Herba Euphorbiae Humifusae, Radix Saposhnikoviae, and Radix Bupleuri. The preparation method comprises the following steps: pulverizing, soaking, decocting and filtering thetraditional Chinese medicine raw materials to obtain liquid medicine; decocting the liquid medicine, carrying out ultrasonic treatment on the liquid medicine, and carrying out centrifugal separation to obtain supernatant; and blending the liquid medicine with the supernatant to obtain the traditional Chinese medicine composition. The intestinal tract contrast agent for X-ray barium enema examination has the advantages that intestinal filling effect is good, clear development is implemented, meanwhile, a lower gastrointestinal mucous membrane is protected, chronic colitis is treated, the medicine can directly reach a diseased region, and meanwhile, a local washing and cleaning effect can further be achieved to achieve purposes of stopping diarrhea and diminishing inflammation, relaxing themuscular spasm and stopping pain, improving local blood circulation and metabolism, enhancing an intestinal immune function and facilitating ulcer healing.